Abstract: An appliance for disinfecting/sterilizing contact lenses having a valve for the venting of gases liberated from the lens solution in the form of a deformable, polymeric plug which is movable between a closed and an open position, depending on the pressure of the gases.

Abstract: A method of disinfecting a soft contact lens with a stabilized aqueous hydrogen peroxide solution having a pH between about 5.5 and about 7.5, a hydrogen peroxide content of between about 0.5 and about 6% by weight, and containing between about 0.003 and about 0.03% by weight of diethylene triamine penta(methylenephosphonic acid) or a physiologically compatable salt thereof, and compositions for use in such method.

Abstract: Cephalin derivatives of the formula I ##STR1## in which R.sup.1 and R.sup.2 each represents, independently of the other, hydrogen or lower alkyl, R.sup.3 represents hydrogen, lower alkoxycarbonyl, carbamoyl or free or protected carboxy, R.sup.4 represents hydrogen or an aliphatic, aromatic, aromatic-aliphatic or cycloaliphatic radical, W represents hydrogen and Z represents a 1,2-dihydroxyethyl, 2-hydroxyethyl or hydroxymethyl group in which at least one hydroxy group is esterified by an aliphatic C.sub.6-30 -carboxylic acid or etherified by an aliphatic C.sub.6-30 -alcohol and in which the other hydroxy group, if present, is free, esterified by an aliphatic C.sub.2-30 -carboxylic acid or etherified by an aliphatic C.sub.1-30 -alcohol, or W represents hydroxymethyl or a hydroxymethyl group that is esterified by an aliphatic C.sub.6-30 -alcohol and Z represents a hydroxymethyl group that is esterified by an aliphatic C.sub.6-30 -carboxylic acid or etherified by an aliphatic C.sub.

Abstract: The invention relates to pharmaceutical preparations containing compounds of formula I ##STR1## in which X represents unsubstituted or substituted amino or a quaternary ammonium salt; halogen, free, etherified or esterified hydroxy; free, etherified, esterified or oxidized mercapto; free or functionally modified carboxyl, free or functionally modified sulfo; acyl; nitro; an unsubstituted or substituted hydrocarbon radical or an unsubstituted or substituted heterocyclic radical, Y represents oxygen, sulfur, sulfinyl or sulfonyl but must be oxygen, sulfinyl or sulfonyl, if X is 1H-imidazol-1-yl, and rings A and B are each unsubstituted or substituted; or pharmaceutically acceptable salts of such compounds that contain a salt-forming group, and to novel compounds of formula I. The compounds are useful e.g. for the treatment of diseases of the respiratory tract and of liver diseases. They are prepared by methods known per se.

Abstract: Rifamycin derivatives of formula ##STR1## wherein R is a radical of the formula ##STR2## in which R.sub.1 is an unsubstituted or substituted biphenylyl radical, and wherein X--X, Y--Y and Z--Z are each vinylene of the formula CH.dbd.CH, or wherein X--X and Y--Y are each ethylene of the formula CH.sub.2 --CH.sub.2 and Z--Z is ethylene or vinylene, and processes for the preparation thereof are described. These compounds can be used as antibacterial and antiviral medicaments.

Abstract: A method of reducing the viscosity of asphaltenic crude oils by incorporating into said crude oil an effective viscosity reducing amount of an oil soluble organic compound having at least one oleophobic and hydrophobic fluoroaliphatic group, and optionally a low viscosity diluent, and compositions thereof.

Abstract: Mono- and di-saccharidyl derivatives that are linked via a bridge member to a cephalin derivative, of the formula I, and processes for their manufacture are described. ##STR1## In the formula, R.sup.1 represents (a) aldohexosyl, (b) D-aldohexosyl that is glycosidically linked in the 4- or the 6-position to D-aldohexosyl, (c) aldopentosyl, (d) 6-deoxyaldohexosyl or (e) 2-acetylamino-2-deoxy-D-aldohexosyl, it being possible for free hydroxy groups present in the radicals mentioned under (a) to (e) above to be peracetylated, X represents oxygen or sulphur, Y represents alkylene having up to 10 carbon atoms in which from 1 to 3 non-terminal methylene groups may be replaced by oxygen, by carbonylimino or by carbonyloxy, R.sup.2 represents hydrogen, carboxy, lower alkoxycarbonyl, benzyloxycarbonyl or carbamoyl, R.sup.3 represents hydrogen and R.sup.4 represents a 1,2-dihydroxy-ethyl, 2-hydroxy-ethyl or hydroxymethyl group in which at least one hydroxy group is esterified by an unsubstituted aliphatic C.sub.

Abstract: An organic solvent soluble active agent containing water-insoluble hydrophilic hydrogel comprising a copolymer of (A) a water-soluble monoolefinic monomer or a mixture thereof optimally containing up to 50% thereof of one or more water-insoluble mono-olefinic monomers and (B) a terminally diolefinic hydrophobic macromer containing polypropylene oxide or polytetramethylene oxide units prepared in the presence of an effective macromer expanding amount of a macromer soluble compound of the formulaR'--R"--O.sub.n R"'where R', R", R"' and n are as defined in the claims, hydrogels useful in the loading of such active agents, their preparation, and use are disclosed.

Abstract: Aromatically substituted azacycloalkylalkanediphosphonic acids of the formula ##STR1## in which R represents an aromatically substituted azacycloaliphatyl radical that is bonded to the group alk by way of a nitrogen atom and that optionally contains an additional nitrogen atom, and alk represents a divalent aliphatic radical, and their salts, can be used for the treatment of illnesses that can be attributed to calcium metabolism disorders. They are manufactured, for example, by reacting a compound of the formulaR--alk--X.sub.3 (IV)in which X.sub.3 represents carboxy, carbamoyl or cyano, with phosphorus acid and phosphorus trichloride and in an intermediate of the formula ##STR2## obtained by starting from compounds of the formula IV in which X.sub.3 represents cyano or carbamoyl and by working up by hydrolysis, or in a salt thereof, replacing the amino group by hydroxy by treatment with nitrous acid.

Abstract: IgE binding factors (IgE-bfs) with IgE suppressor (IgE-SF) activity obtainable from human colostrum in an enriched form, a method for the prevention and/or the treatment of allergy by administering the IgE-bfs and pharmaceutical compositions comprising said IgE-bfs.

Abstract: Novel 4-acylresorcinol ethers of the formula ##STR1## in which R.sub.1 represents lower alkyl, R.sub.2 represents lower alkyl, lower alkenyl or lower alkynyl, R.sub.3 represents hydrogen, lower alkoxy, trifluoromethyl or halogen, alk represents an alkylene radical, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.9 and a radical R.sub.7 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.10, R.sub.6 represents hydrogen, lower alkyl, halogen, trifluoromethyl, optionally esterified or amidated carboxy, cyano or lower alkanoyl, R.sub.8 represents optionally esterified or amidated carboxy, or 5-tetrazolyl, R.sub.9 represents hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R.sub.

Abstract: A synthetic resin based on a polystyrene that can be used as a support for solid phase peptide synthesis and that has been cross-linked with from 0 to 5 mol % of divinyl benzene, characterized in that it has been substituted at benzene rings of its skeletal structure by groups of the formula ##STR1## in which X represents --O-- or --NH-- and R represents C.sub.1 -C.sub.4 -alkyl, as a support renders possible the solid phase synthesis of peptides and peptide amides that are, if desired, protected at the N-terminal and/or at other functional groups. The resin is manufactured by reaction of a customary chloromethylated polystyrene resin with an alkali metal salt of the corresponding 4-hydroxybenzophenone and subsequent reduction of the carbonyl group and, optionally, amination.

Abstract: The instant invention relates to water-soluble anionic polysaccharides bound to perfluoroalkyl cationic surfactants. Polymer complexes are formed which are especially useful for fighting fires of hydrophilic or polar liquids. They have the unique property of forming an impervious gel when foamed with suitable surfactants and projected onto burning liquids. The gelatinous blanket is resistant to the fuel and protects the foam blanket from destruction. Consequently, superior fire-fighting agents can be prepared for fires which are otherwise very difficult to extinguish.

Abstract: Hydrophilic modifier monomers of the formula [X-T].sub.z 'G are disclosed wherein X is a reactive group, G is a hydrophilic group and T is a divalent linking group, z' being a number up to the available valence of G, excess G valences being taken up by hydrogen. The monomers of the invention can be used to boost the hydrophilic nature of a wide variety of polymeric materials or be polymerized themselves with varying degrees of copolymerizable monomers. They are particularly suited for making hydrophilic contact lens materials.

Abstract: 1-Phenyl-3-azabicyclo[3.1.1]-heptane-2,4-diones of the formula ##STR1## in which R.sub.1 represents hydrogen or a saturated or unsaturated, aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, aromatic or aromatic-aliphatic hydrocarbon radical having up to and including 18, preferably up to and including 12, carbon atoms, R.sub.2 represents hydrogen, lower alkyl, sulpho or acyl, R.sub.3 represents hydrogen or lower alkyl and R.sub.4 represents hydrogen, lower alkyl, phenyl or phenyl substituted by --N(R.sub.2)(R.sub.3), and salts of these compounds, have valuable pharmacological properties, are effective as aromatase inhibitors and can therefore be used for the treatment of hormone-dependent diseases, especially mammary carcinoma.

Abstract: Contact lenses which are optically clear, wettable, flexible, of high oxygen permeability and substantially non-swellable in the aqueous ocular environment of use, of a polymer containing polyoxyalkylene backbone units are disclosed, as well as the preparation thereof and methods of treating vision defects therewith.

Abstract: The invention relates to a therapeutic system for peroral administration and having systemic action, which system is in the form of a coated and/or laminated monocompartment system for administering carbamazepine. The therapeutic system comprises(a) a wall made of a material which is permeable to water and impermeable to the components of the drug-containing core,(b) a core containing finely particulate carbamazepine as drug and, as auxiliaries, a protective colloid that inhibits the crystal growth of carbamazepine in the presence of water, a swellable hydrophilic polymer and, optionally, a water-soluble compound for inducing osmosis and/or further pharmaceutically acceptable excipients, and(c) a passageway through the wall (a) for delivering the core components to the environmental body fluid. The therapeutic system can be used as an anticonvulsive for the treatment of convulsive states, especially epileptic states.

Abstract: The invention concerns the use of a compound with diuretic properties and of a magnesium supplementation in the form of magnesium monoaspartate hydrochloride, magnesium oxide, magnesium hydroxide or magnesium carbonate, and optionally of a potassium supplementation, and pharmaceutical preparations comprising a compound with diuretic properties and a magnesium supplementation in the form of magnesium monoasparate hydrochloride, magnesium oxide, magnesium hydroxide, or magnesium carbonate and optionally a potassium supplementation.

Abstract: A method of treating a premature neonatal infant of a gestational age between about 24 and about 35 weeks with a pharmaceutically acceptable, systemically active, substantially skin compatible, water-soluble neonatal therapeutic agent having a molecular weight below about 5000, and which agent is substantially non-transmissable through normal mature intact human skin, comprising:(a) applying to the intact neonatal skin of said infant a transdermal device comprising (i) a backing member, (ii) a substantially shape retaining hydrogel reservoir having a water content of between about 5 percent and about 95 percent preferably between 10 percent and 80 percent by weight of said reservoir and containing an effective amount of said agent, (iii) a skin contacting surface of predetermined area, and (iv) means for maintaining said reservoir in material transmitting relationship to said skin;(b) maintaining said skin contacting surface of said device in material transmitting relationship to said intact neonatal skin of

Abstract: Compounds of the formula ##STR1## in which R represents a carbocyclic or heterocyclic aryl radical,R.sub.1 represents lower alkyl, one of the groups R.sub.2 and R.sub.3 represents lower alkyl and the other represents lower alkyl, cyano or amino,X represents oxygen or the group --NH--, andAlk represents lower alkylene which separates the group X from the ring nitrogen atom by at least two carbon atoms,Y represents the group --CHOH-- or --(C.dbd.O)--, andAr.sub.1 represents a monocyclic aryl or heteroaryl radical,Ar.sub.1 being other than unsubstituted phenyl ifR.sub.1, R.sub.2 and R.sub.3 each represents lower alkyl, X represents oxygen, Alk represents straight-chain alkylene having from 2 to 4 carbon atoms, Y represents the group --(C.dbd.O)-- and R has the meaning given, and salts thereof have cardiovascular, especially coronary-dilatory and antihypertensive properties.